Magle Group applies for extended patent protection of its DSM technology in Europe
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that the company has filed a new patent application for its DSM (Degradable Starch Microspheres) technology with the European Patent Office (EPO). The patent application covers an expanded use of DSM products in the embolization of tumors and is intended to support the initiation of new development projects, in line with Magle Group’s expansion strategy.
The patent application covers microspheres that are complexed to a radioactive metal, to be used in dosimetry planning before the treatment of liver malignancies through embolization.
“Magle Group sees great potential for DSM-based products in tumor embolization, and the new patent application will further strengthen the rationale for expanding our portfolio of development projects within this underserved and commercially attractive area,“ says Camilla Gummesson, Director of R&D at Magle Group.
Provided the patent application is approved, it will provide intellectual property protection in relevant territories until 2043.
